<?xml version='1.0' encoding='utf-8'?>
<document id="25505649"><sentence text="Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz."><entity charOffset="138-147" id="DDI-PubMed.25505649.s1.e0" text="efavirenz" /></sentence><sentence text="To treat malaria, HIV-infected patients normally receive artemether (80 mg twice daily) concurrently with antiretroviral therapy and drug-drug interactions can potentially occur"><entity charOffset="57-67" id="DDI-PubMed.25505649.s2.e0" text="artemether" /></sentence><sentence text=" Artemether is a substrate of CYP3A4 and CYP2B6, antiretrovirals such as efavirenz induce these enzymes and have the potential to reduce artemether pharmacokinetic exposure"><entity charOffset="73-82" id="DDI-PubMed.25505649.s3.e0" text="efavirenz" /></sentence><sentence text=" The aim of this study was to develop an in vitro in vivo extrapolation (IVIVE) approach to model the interaction between efavirenz and artemether"><entity charOffset="122-131" id="DDI-PubMed.25505649.s4.e0" text="efavirenz" /><entity charOffset="136-146" id="DDI-PubMed.25505649.s4.e1" text="artemether" /><pair ddi="false" e1="DDI-PubMed.25505649.s4.e0" e2="DDI-PubMed.25505649.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25505649.s4.e0" e2="DDI-PubMed.25505649.s4.e1" /></sentence><sentence text=" Artemether dose adjustments were then simulated in order to predict optimal dosing in co-infected patients and inform future interaction study design" /><sentence text="" /><sentence text="In vitro data describing the chemical properties, absorption, distribution, metabolism and elimination of efavirenz and artemether were obtained from published literature and included in a physiologically based pharmacokinetic model (PBPK) to predict drug disposition simulating virtual clinical trials"><entity charOffset="106-115" id="DDI-PubMed.25505649.s7.e0" text="efavirenz" /><entity charOffset="120-130" id="DDI-PubMed.25505649.s7.e1" text="artemether" /><pair ddi="false" e1="DDI-PubMed.25505649.s7.e0" e2="DDI-PubMed.25505649.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25505649.s7.e0" e2="DDI-PubMed.25505649.s7.e1" /></sentence><sentence text=" Administration of efavirenz and artemether, alone or in combination, were simulated to mirror previous clinical studies and facilitate validation of the model and realistic interpretation of the simulation"><entity charOffset="19-28" id="DDI-PubMed.25505649.s8.e0" text="efavirenz" /><entity charOffset="33-43" id="DDI-PubMed.25505649.s8.e1" text="artemether" /><pair ddi="false" e1="DDI-PubMed.25505649.s8.e0" e2="DDI-PubMed.25505649.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25505649.s8.e0" e2="DDI-PubMed.25505649.s8.e1" /></sentence><sentence text=" Efavirenz (600 mg once daily) was administered to 50 virtual subjects for 14 days"><entity charOffset="1-10" id="DDI-PubMed.25505649.s9.e0" text="Efavirenz" /></sentence><sentence text=" This was followed by concomitant administration of artemether (80 mg eight hourly) for the first two doses and 80 mg (twice daily) for another two days"><entity charOffset="52-62" id="DDI-PubMed.25505649.s10.e0" text="artemether" /></sentence><sentence text="" /><sentence text="Simulated pharmacokinetics and the drug-drug interaction were in concordance with available clinical data" /><sentence text=" Efavirenz induced first pass metabolism and hepatic clearance, reducing artemether Cmax by 60% and AUC by 80%"><entity charOffset="1-10" id="DDI-PubMed.25505649.s13.e0" text="Efavirenz" /></sentence><sentence text=" Dose increases of artemether, to correct for the interaction, were simulated and a dose of 240 mg was predicted to be sufficient to overcome the interaction and allow therapeutic plasma concentrations of artemether"><entity charOffset="205-215" id="DDI-PubMed.25505649.s14.e0" text="artemether" /></sentence><sentence text="" /><sentence text="The model presented here provides a rational platform to inform the design for a clinical drug interaction study that may save time and resource while the optimal dose is determined empirically" /><sentence text=" Wider application of IVIVE could help researchers gain a better understanding of the molecular mechanisms underpinning variability in drug disposition" /><sentence text="" /></document>